Last updated: October 29, 2026
Locametz is a radiopharmaceutical kit used to prepare gallium-68 gozetotide injection for PSMA PET imaging in prostate cancer. Its formulation uses a low-mass, lyophilized excipient system centered on gentisic acid and sodium acetate trihydrate. The commercial opportunity is concentrated in GMP excipient supply, sterile kit manufacturing, radiopharmacy workflow, quality control, and regional distribution rather than in conventional finished-dose formulation.
Locametz is not a biologic and does not create a biosimilar market. Potential competition would come from an abbreviated or full generic radiopharmaceutical kit, competing PSMA imaging agents, hospital-compounded products where legally permitted, and alternative PET tracers. The principal barriers are radiolabeling performance, sterility assurance, radionuclide logistics, validated quality control, and short product handling windows.
What is Locametz and how is it formulated?
Locametz is Novartis Pharmaceuticals Corporation's kit for the preparation of gallium-68 gozetotide injection. The FDA approved Locametz in March 2022 under NDA 215834 for PET imaging of PSMA-positive lesions in patients with prostate cancer. The kit itself is not administered before radiolabeling. A radiopharmacy adds gallium-68 chloride to the vial under controlled conditions before intravenous administration. [1]
Locametz composition per vial
| Component |
Function |
Commercial relevance |
| Gozetotide, 25 micrograms |
PSMA-targeting peptide and active ligand |
Requires peptide GMP control, identity testing and impurity profiling |
| Gentisic acid, 28 mg |
Stabilizer and radiolysis-control excipient |
Requires high-purity, low-metal, sterile or aseptically controlled supply |
| Sodium acetate trihydrate, 14 mg |
Buffering agent and pH-control excipient |
Requires tight control of water content, purity and solution performance |
| Gallium-68 chloride |
Added radiolabel, not supplied as the finished kit component |
Requires generator or cyclotron access and radionuclide quality testing |
The U.S. prescribing information identifies gentisic acid and sodium acetate trihydrate as inactive ingredients in the kit. The final radiolabeled product also contains the components introduced during radiolabeling, including the gallium-68 source and the approved preparation medium. [1]
What is the excipient strategy for Locametz?
The Locametz excipient strategy is designed around four technical requirements: protect the peptide during storage, limit radiolysis after radiolabeling, maintain suitable pH during complexation, and support a short radiopharmacy preparation process.
Why does Locametz use gentisic acid?
Gentisic acid is a phenolic antioxidant that can reduce oxidative degradation in radiolabeled peptide formulations. Radiopharmaceuticals are exposed to radiolysis generated by the radionuclide and aqueous solution environment. A suitable antioxidant can reduce oxidation of the peptide, chelator or other vulnerable molecular groups.
For Locametz, gentisic acid has several commercial advantages:
- It is a low-molecular-weight excipient with established pharmaceutical use.
- It can be incorporated into a lyophilized kit.
- It is compatible with a short preparation and administration cycle.
- It may reduce the need for more complex antioxidant systems.
- It creates a supply requirement for pharmaceutical-grade material with controlled trace-metal content.
The most commercially relevant quality attributes are identity, assay, related substances, residual solvents, elemental impurities, bioburden, endotoxin status where applicable, and compatibility with the lyophilization cycle.
Why is sodium acetate trihydrate used?
Sodium acetate trihydrate provides buffering capacity. Radiolabeling with gallium-68 requires controlled chemical conditions, including suitable pH and complexation performance. Buffer selection affects labeling yield, peptide integrity, generator eluate compatibility and final injection quality.
Sodium acetate trihydrate is widely available and generally less differentiated than gentisic acid. The commercial opportunity therefore lies less in proprietary chemistry and more in:
- GMP-grade supply;
- lot-to-lot consistency;
- low trace-metal burden;
- validated water content;
- sterile manufacturing or controlled aseptic processing;
- reliable global availability.
A supplier seeking Locametz-related business would need to demonstrate consistent performance in the complete kit formulation rather than only meet a general compendial specification.
What excipient characteristics matter most for Locametz manufacturing?
Trace metals
Trace metals can compete with gallium for chelation or reduce radiolabeling performance. Excipient specifications should therefore address metals such as iron, copper, zinc and other elements relevant to gallium complexation and peptide stability.
A conventional excipient specification may be inadequate if it does not control the elemental profile tightly enough for radiopharmaceutical use.
Radiolysis control
The antioxidant must control degradation without creating unacceptable impurities, affecting radiochemical purity or complicating release testing. The target is not simply chemical stability before labeling. The relevant performance measure is stability through labeling, dispensing and the approved shelf-life of the radiolabeled preparation.
Lyophilization compatibility
The excipient system must support:
- cake formation;
- reconstitution speed;
- low residual moisture;
- consistent vial-to-vial performance;
- container closure integrity;
- acceptable radiolabeling yield after storage.
For a kit product, the lyophilized cake is part of the manufacturing process and the radiopharmacy user experience. Poor reconstitution or variable labeling performance creates operational risk even when the nominal formulation is correct.
Sterility and endotoxin control
Locametz is an injectable radiopharmaceutical preparation. Excipients, vials, stoppers and the fill-finish process must support sterility assurance and applicable endotoxin limits. Suppliers that offer only bulk chemical material may not capture the highest-value portion of the market. Sterile, ready-to-use or validated pharmaceutical-grade supply has greater strategic value.
What commercial opportunities exist in Locametz excipients?
1. Pharmaceutical-grade gentisic acid
Gentisic acid is the most differentiated excipient opportunity in the formulation. A qualified supplier could compete through:
- dedicated GMP production;
- low-metal specifications;
- sterile or low-bioburden grades;
- validated lyophilization performance;
- dual-source qualification;
- regional inventory near radiopharmaceutical manufacturing sites.
The addressable volume is likely modest because the quantity per vial is small. The value proposition is therefore qualification status, quality assurance and supply continuity rather than bulk volume.
2. Sodium acetate trihydrate supply
Sodium acetate trihydrate is a lower-differentiation opportunity. It can still generate commercial value when bundled with:
- pharmaceutical-grade documentation;
- elemental impurity data;
- water-content controls;
- rapid batch release;
- global regulatory support;
- continuity of supply.
A supplier with both sodium acetate trihydrate and gentisic acid could offer a more complete excipient package for radiopharmaceutical kit manufacturers.
3. Sterile vial and closure systems
Locametz depends on container closure performance through storage, transport and radiopharmacy reconstitution. Opportunities include:
- low-extractable glass vials;
- elastomeric stoppers validated for lyophilized peptide kits;
- radiopharmaceutical-compatible seals;
- container closure integrity testing;
- ready-to-use sterile components.
These components are not excipients in the narrow sense, but they are central to the formulation's commercial performance.
4. Radiopharmacy preparation systems
The kit model creates demand for workflow products that reduce operator time and variability:
- automated radiolabeling modules;
- disposable synthesis cassettes;
- validated transfer sets;
- dose calibration and dispensing systems;
- integrated radiochemical purity testing;
- digital batch records.
The highest-value opportunity may be the combination of kit, equipment and service support rather than excipient sales alone.
5. Quality-control services
Radiopharmacy and manufacturing sites require testing for:
- radiochemical identity;
- radiochemical purity;
- chemical purity;
- peptide-related impurities;
- residual solvents;
- pH;
- sterility and endotoxin;
- radionuclidic identity and purity;
- activity concentration.
Contract laboratories with validated methods for gallium-68 peptide products can support both originator and competing kit manufacturers.
What manufacturing and intellectual-property barriers affect Locametz?
The principal manufacturing barriers are operational rather than based on the two disclosed excipients. A competing product would need to reproduce the complete product performance, including:
- Peptide and chelator quality.
- Gallium-68 labeling yield.
- Radiochemical purity.
- Stability after labeling.
- Sterility and endotoxin control.
- Reconstitution time.
- Suitable shelf life for the unlabeled kit.
- Radiopharmacy instructions that are practical across different generator and equipment configurations.
The formulation may be difficult to copy commercially even if gentisic acid and sodium acetate trihydrate are readily available. The relevant know-how can reside in peptide synthesis, purification, lyophilization, container closure, labeling conditions, analytical methods and manufacturing controls.
What patents protect Locametz?
Locametz's public regulatory documents establish the product, active ligand and formulation components, but they do not provide a complete patent landscape. Patent risk should be separated into:
- composition-of-matter patents covering gozetotide or related PSMA ligands;
- chelator and radiolabeling technology;
- formulation and stabilization claims;
- lyophilization and kit claims;
- manufacturing process claims;
- method-of-use claims for PSMA PET imaging;
- device or radiopharmacy preparation claims.
The two named excipients are generally available chemicals. Their use in Locametz is therefore less likely to create a standalone exclusionary position than claims directed to the ligand, kit configuration, labeling process or specific formulation ranges.
What is the Orange Book status of Locametz?
Locametz is an FDA-approved prescription drug marketed under NDA 215834. The FDA label confirms the approved indication and kit presentation. [1]
Orange Book patent listings and regulatory exclusivity should be reviewed separately from the prescribing information. The relevant commercial questions are:
| Issue |
Business implication |
| NDA reference-listed-drug status |
Determines the pathway for an abbreviated application |
| Listed patents |
May delay or prevent an abbreviated launch |
| Paragraph IV certification |
Creates potential patent litigation and a possible 30-month stay |
| New chemical entity exclusivity |
May restrict abbreviated filing during the protected period |
| Three-year exclusivity |
Could apply if supported by qualifying clinical investigations |
| Pediatric exclusivity |
Could add six months if granted |
| Method-of-use claims |
May require labeling or carve-out analysis |
| Kit and formulation claims |
Could affect a competing radiolabeled product even where the excipients are public |
No biosimilar pathway applies because gozetotide is a synthetic peptide radiopharmaceutical rather than a licensed biologic. A future competitor would more likely pursue an abbreviated drug application, a 505(b)(2) application, or another applicable pathway depending on formulation, labeling and comparative data.
When could Locametz face generic or competing-product entry?
The timing depends on Orange Book listings, statutory exclusivity, patent validity and the regulatory pathway used by the challenger. A generic or 505(b)(2) entrant would face a more complex launch decision than a conventional oral solid dosage product.
Generic launch scenarios
| Scenario |
Likely commercial effect |
| No blocking patent and no remaining exclusivity |
Earlier kit competition, price pressure and hospital contracting |
| Paragraph IV challenge followed by litigation |
Delayed entry, legal-cost escalation and possible settlement |
| Non-infringing alternative formulation |
Potential entry around formulation claims |
| Competing PSMA PET tracer |
Market-share competition without direct generic substitution |
| Regional radiopharmacy preparation |
Local competition where compounding and regulatory rules permit |
| Manufacturing failure or supply disruption |
Temporary share shifts to alternative tracers or suppliers |
The radiopharmaceutical market can support multiple products because hospitals value reliable radionuclide access, imaging capacity, reimbursement, local preparation capability and physician familiarity. Generic substitution may therefore be less automatic than in a standard tablet market.
Which products compete with Locametz?
Locametz competes primarily with other PSMA PET imaging agents and, in some settings, with non-PSMA imaging approaches. The most direct U.S. comparator is piflufolastat F 18 injection, marketed as Pylarify by Lantheus. Other PSMA imaging products may compete by geography, radionuclide availability, site infrastructure, reimbursement and clinical preference.
| Product |
Radionuclide |
Product model |
Main competitive variable |
| Locametz |
Gallium-68 |
Radiolabeled kit |
Generator or cyclotron access, kit logistics and preparation workflow |
| Pylarify |
Fluorine-18 |
Ready-to-use radiopharmaceutical |
Longer physical half-life and centralized distribution potential |
| Other PSMA agents |
Gallium-68 or fluorine-18 |
Finished dose or kit |
Local availability, regulatory status and clinical adoption |
Gallium-68 has a short physical half-life, which favors local or regional preparation. Fluorine-18 has a longer half-life, which can support broader distribution from centralized manufacturing sites. This difference affects the commercial value of Locametz excipients: a successful kit requires dependable local radiopharmacy execution rather than only finished-product distribution.
What is the revenue exposure for Locametz?
Public company reporting generally combines radiopharmaceutical franchises or reports products within broader oncology portfolios. Product-level Locametz revenue may not be separately disclosed in all reporting periods. The commercial value of Locametz is linked to:
- PSMA PET procedure volume;
- prostate cancer diagnosis and staging;
- use in biochemical recurrence;
- availability of gallium-68 generators or cyclotron supply;
- reimbursement;
- hospital radiopharmacy capacity;
- competition from fluorine-18 PSMA imaging agents;
- expansion of PSMA-targeted treatment pathways.
The excipient opportunity is a small fraction of total product revenue because each vial uses only milligram quantities of excipients. The higher-value opportunities are qualification, sterile supply, analytical services, kit manufacturing, equipment and distribution.
How strong is the Locametz excipient strategy?
The strategy is strong from a manufacturability perspective because it uses a simple, compact excipient system. Gentisic acid provides stabilization value, while sodium acetate trihydrate supports pH control. Neither excipient requires a complex delivery technology.
Its main weaknesses are commercial:
- excipient volumes are low;
- the chemicals are not highly exclusive;
- supply substitution may be technically possible after qualification;
- product value depends heavily on the peptide and radiolabeling process;
- competing PSMA tracers can bypass direct kit substitution.
The strongest defensible position is likely to reside in the integrated kit and process, not in ownership of the individual excipients.
Key Takeaways
- Locametz is a lyophilized gallium-68 gozetotide kit approved under FDA NDA 215834.
- Its disclosed excipients are gentisic acid and sodium acetate trihydrate.
- Gentisic acid is the more differentiated excipient opportunity because of its role in oxidative and radiolytic stability.
- Sodium acetate trihydrate is commercially attractive mainly through GMP quality, low-metal control and supply reliability.
- The largest opportunities are sterile excipient supply, container closure systems, radiopharmacy equipment, analytical testing and kit manufacturing.
- Locametz has no biosimilar pathway because gozetotide is a synthetic peptide radiopharmaceutical.
- Generic entry would face peptide, radiolabeling, sterility, logistics and patent barriers.
- The main competitive threat is not only a generic Locametz kit. Fluorine-18 PSMA products can compete through longer half-life and centralized distribution.
- Patent risk should focus on gozetotide, chelation, kit, formulation, manufacturing and method-of-use claims rather than the generic excipients alone.
FAQs
Does Locametz contain gentisic acid?
Yes. The FDA prescribing information identifies gentisic acid as an inactive ingredient at 28 mg per vial. [1]
Is sodium acetate trihydrate a proprietary Locametz excipient?
No. Sodium acetate trihydrate is a widely used pharmaceutical buffer. Locametz-related value would arise from pharmaceutical-grade quality, specification control and qualification in the complete kit process.
Can a manufacturer replace gentisic acid in a competing Locametz product?
A replacement would require formulation development, comparative radiolabeling data, stability testing, analytical validation and regulatory support. The fact that gentisic acid is commercially available does not make substitution automatic.
Is Locametz interchangeable with Pylarify?
No. Locametz and Pylarify use different radiopharmaceutical formats and radionuclides. Their preparation, distribution, half-life, labeling and operational requirements differ.
Are there biosimilar versions of Locametz?
No. Locametz is not a biologic product. Potential competitors would generally use generic, 505(b)(2), or another applicable drug-development pathway rather than the biosimilar pathway.
References
-
U.S. Food and Drug Administration. (2022). Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information. Novartis Pharmaceuticals Corporation.
-
European Medicines Agency. (2022). Locametz: EPAR product information. European Medicines Agency.
-
United States Pharmacopeia. (2023). General chapter <825>: Radiopharmaceuticals, preparation, compounding, dispensing, and repackaging. United States Pharmacopeial Convention.
